Plus links on accumulators and the prospects for the lame-duck session
And JAMA offers a clip-n-save piece on ways consumers can find cheaper meds
Plus the NYT published the second piece in its PBM series, showing how the middlemen are killing pharmacies
I know, I know. It's a Saturday. Pardon the interruption.
And both sides draw some battle lines around patent reform
And some great research from NPC further details the way that oncology drug development might be imperilled by the IRA
And UnitedHealth earnings dropped today, showing Optum Rx -- as usual -- generating oodles and oodles of cash for the health care giant
Otherwise: it's a pretty slow day, news-wise. We can all catch our breath.
Plus a CBO report on obesity and Harris' latest plan to use drug-price-reduction as a piggybank for other policy priorities
Plus a Health Affairs study makes even more plain why the IRA puts oncology at risk
Plus new data shows that 340B appears to 'work' at FQHCs. If only we could say the same for big nonprofit hospitals
Plus a smart paper on why inventing drugs is too expensive and risky to be left to the government
